Prevalence and impact of anxiety and depression among COPD patients

Not yet recruiting

Conditions: Chronic obstructive pulmonary disease, unspecified,

Registration Number: CTRI/2025/05/086664

Lead Sponsor: SINCHANA V SHETTY

Brief Summary: Chronic Obstructive Pulmonary Disease (COPD) is a progressive, preventable, and treatable lung disease characterized by persistent airflow limitation. It is mainly caused by long-term exposure to harmful particles, particularly cigarette smoke, with additional contributions from genetic factors, environmental exposures, occupational hazards, respiratory infections, and childhood asthma. In susceptible individuals, inhalational exposure triggers inflammation, leading to a protease-antiprotease imbalance and resulting in lung tissue damage. Chronic inflammation, oxidative stress, and mechanical stress continue to worsen the condition even after smoking cessation. COPD diagnosis is made using spirometry, which measures airflow obstruction. Treatment includes bronchodilators like beta-2 agonists (e.g., salbutamol, formoterol) and antimuscarinics (e.g., ipratropium, tiotropium), along with cautious use of cardioselective beta-blockers for patients with cardiovascular disease. Non-pharmacologic strategies, such as smoking cessation and pulmonary rehabilitation, are essential for improving quality of life. The primary objectives of this study are to assess the prevalence of anxiety and depression in COPD patients and to understand their impact on disease progression. Secondary objectives include evaluating patients’ quality of life, smoking prevalence among hospitalized COPD patients, the frequency of sleep disturbances, and medication adherence. Understanding these factors will help in developing better management approaches to improve patient outcomes and overall well-being.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 100

Inclusion Criteria

Patients with primary diagnosis of COPD COPD patients aged 18 years and above Patient who signed written informed consent.

Exclusion Criteria

Patients under 18 years of age.
mental disorders impairing capacity for informed consent Patients who are unresponsive, unconscious and comatose Patients who are not willing to participate in the study.

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This study on Chronic Obstructive Pulmonary Disease patients will likely reveal a high prevalence of anxiety and depression, exacerbating symptoms and worsening quality of life. Findings may also show poorer quality of life, high smoking prevalence, sleep disturbances and medication adherence challenges.	0,15,30

Secondary Outcome Measures

Name	Time	Method

Trial Locations

Locations (1): Father Muller Medical College Hospital
🇮🇳
Kannada, KARNATAKA, India
Father Muller Medical College Hospital
🇮🇳Kannada, KARNATAKA, India
Sinchana V Shetty
Principal investigator
8296825697
sinchuvshetty@gmail.com